Skip directly to search Skip directly to A to Z list Skip directly to page options Skip directly to site content

Volume 23, Number 1—January 2017

CME ACTIVITY - Research

Analysis of Anthrax Immune Globulin Intravenous with Antimicrobial Treatment in Injection Drug Users, Scotland, 2009–2010

Xizhong Cui1, Leisha D. Nolen1, Junfeng Sun, Malcolm Booth, Lindsay Donaldson, Conrad P. Quinn, Anne E. Boyer, Katherine Hendricks, Sean Shadomy, Pieter Bothma, Owen Judd, Paul McConnell, William A. Bower, and Peter Q. EichackerComments to Author 
Author affiliations: National Institutes of Health, Bethesda, Maryland, USA (X. Cui, J. Sun, P.Q. Eichacker); Centers for Disease Control and Prevention, Atlanta, Georgia, USA (L.D. Nolen, C.P. Quinn, A.E. Boyer, K. Hendricks, S. Shadomy, W.A. Bower); Glasgow Royal Infirmary, Glasgow, UK (M. Booth, L. Donaldson); James Paget University Hospital, Norfolk, UK (P. Bothma); Royal Derby Hospital, Derby, UK (O. Judd); Crosshouse Hospital, Kilmarnock, UK (P. McConnell)

Main Article

Figure 2

SOFA scores of injection drug users who did and did not receive AIG-IV, Scotland, UK, 2009–2010. A) Individual SOFA scores for patients who did or did not receive AIG-IV and did or did not survive. B) Proportion of patients who did or did not receive AIG-IV for those who had admission SOFA scores of 0–5 and a low risk for death and for those with SOFA scores of 6–11 and a higher risk for death. AIG-IV, anthrax immune globulin intravenous; SOFA, sequential organ failure.

Figure 2. SOFA scores of injection drug users who did and did not receive AIG-IV, Scotland, UK, 2009–2010. A) Individual SOFA scores for patients who did or did not receive AIG-IV and did or did not survive. B) Proportion of patients who did or did not receive AIG-IV for those who had admission SOFA scores of 0–5 and a low risk for death and for those with SOFA scores of 6–11 and a higher risk for death. AIG-IV, anthrax immune globulin intravenous; SOFA, sequential organ failure.

Main Article

1These authors contributed equally to this article.

TOP